About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Foxp3tm9(EGFP/cre/ERT2)Ayr
targeted mutation 9, Alexander Y Rudensky
MGI:4950935
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Pgdtm1.1Pse/Pgdtm1.1Pse
Foxp3tm9(EGFP/cre/ERT2)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J MGI:7657737
cn2
Foxp3tm9(EGFP/cre/ERT2)Ayr/Foxp3+
Il1r2tm1.1Mchc/Il1r2tm1.1Mchc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac MGI:7643356


Genotype
MGI:7657737
cn1
Allelic
Composition
Pgdtm1.1Pse/Pgdtm1.1Pse
Foxp3tm9(EGFP/cre/ERT2)Ayr/Foxp3+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Foxp3tm9(EGFP/cre/ERT2)Ayr mutation (1 available); any Foxp3 mutation (56 available)
Pgdtm1.1Pse mutation (0 available); any Pgd mutation (21 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• injected B16F10 tumor model in tamoxifen-treated mice




Genotype
MGI:7643356
cn2
Allelic
Composition
Foxp3tm9(EGFP/cre/ERT2)Ayr/Foxp3+
Il1r2tm1.1Mchc/Il1r2tm1.1Mchc
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Foxp3tm9(EGFP/cre/ERT2)Ayr mutation (1 available); any Foxp3 mutation (56 available)
Il1r2tm1.1Mchc mutation (0 available); any Il1r2 mutation (32 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show altered ratios of naive and effector/central memory CD4+ and CD8+ T cells in the spleen
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show increased CD4+ T cell numbers in the spleen
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show an increase in T follicular cells
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show expanded germinal center (increased GL7/B220+ B cells)
• while GCs are expanded, they show normal gross morphology with no increase in follicle size but more GL7+ area per follicle
• however, mice do not show increased GC reactions after a booster immunization of sRBCs
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show altered adaptive response after immunization, with more T follicular (Tfol) cells but no change in the ratio of T follicular helper (Tfh) to T follicular regulatory (Tfr) cells, expanded germinal centers (GCs; increased GL7/B220+ B cells) and higher titers of serum anti-sRBC IgG
• tamoxifen-treated mice challenged with sRBC immunization show increased numbers of CD4+ T cells and altered ratios of nave and effector/central memory CD4+ and CD8+ T cells in the spleen
• tamoxifen-treated mice challenged with OVA/Alum show increased Tfol cells and expanded GCs
• tamoxifen-treated mice still show increased Tfol cells and CD4+ T cells, altered ratios of CD4+/CD8+ subtypes, and increased IFN-gamma expression in CD4+/CD8+ T cells after a booster immunization of sRBCs
• however, splenic Treg level is not altered in tamoxifen-treated mice challenged with sRBC
• however, mice do not show increased GC reactions after a booster immunization of sRBCs, with titer or serum anti-sRBC IgG no different from controls and no higher than those seen after a single immunization
• administration of Anakinra (IL-1RA) reverses the increased responses
• tamoxifen-treated mice challenged with sRBC immunization show higher titers of serum anti-sRBC IgG
• however, mice show no differences in titer of serum anti-sRBC IgG after a booster immunization of sRBCs from controls and no higher levels than those seen after a single immunization

hematopoietic system
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show altered ratios of naive and effector/central memory CD4+ and CD8+ T cells in the spleen
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show increased CD4+ T cell numbers in the spleen
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show an increase in T follicular cells
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show expanded germinal center (increased GL7/B220+ B cells)
• while GCs are expanded, they show normal gross morphology with no increase in follicle size but more GL7+ area per follicle
• however, mice do not show increased GC reactions after a booster immunization of sRBCs
• tamoxifen-treated mice challenged with sRBC immunization show higher titers of serum anti-sRBC IgG
• however, mice show no differences in titer of serum anti-sRBC IgG after a booster immunization of sRBCs from controls and no higher levels than those seen after a single immunization





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
06/12/2024
MGI 6.13
The Jackson Laboratory